LEIDEN, NETHERLANDS--(Marketwire - November 12, 2008) - As part of the Company's recently announced strategic focus on developing controlled release formulations for clients, OctoPlus N.V. ("OctoPlus" or "the Company") (Euronext: OCTO) announces today that it has signed a new drug delivery technology evaluation contract with a US-based biotech company.
